Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Authors: Kwon Young Nam , Kim Boram , Kim Jun-Soon , Park Kyung Seok , Seo Da-Young , Kim Hyunjin , Lee Eun-Jae , Lim Young-Min , Ju Hyunjin , Chung Yeon Hak , Min Ju-Hong , Nam Tai-Seung , Kim Sooyoung , Sohn Eunhee , Shin Kyong Jin , Seok Jin Myoung , Kim Sunyoung , Bae Jong Seok , Lee Sukyoon , Oh Seong-il , Jung Yu Jin , Park Jinseok , Kim Seung Hyun , Kim Ki Hoon , Kim Ho Jin , Jung Jae Ho , Kim Seong-Joon , Kim Seung Woo , Jang Myoung-jin , Sung Jung-Joon , Waters Patrick , Shin Ha Young , Kim Sung-Min 
Published: September 2024

Importance

A proportion of people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have a relapsing disease course and persistent anti–myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) seropositivity. Few studies have investigated whether treatment of the first MOGAD attack is associated with the long-term disease course and/or MOG-IgG seronegative conversion.

Objective

To investigate the association of time to treat the first acute MOGAD attack with relapse risk and MOG-IgG serostatus.

Design, Setting, and Participants

This was a retrospective, nationwide, multicenter cohort study involving 14 secondary or tertiary hospitals in South Korea between November 2009 and August 2023. People with adult-onset MOGAD, who either had a relapse or were followed up for more than 12 months after disease onset and had a detailed medical record of their first attack, were included. Individuals were excluded for adolescent-onset MOGAD or short disease duration.

Exposures

Patients were categorized based on the time to treat the first acute MOGAD attack: early (&amp;lt;5 days), intermediate (5-14 days), and late (not treated within 14 days).

Main Outcomes and Measures

A multivariable analysis for clinical and treatment factors associated with relapsing disease course and/or MOG-IgG seronegative conversion. Further subgroup analyses were conducted among those without long-term nonsteroidal immunosuppressant (NSIS) maintenance treatment.

Results

Among the 315 individuals screened, 75 were excluded. A total of 240 patients (median [IQR] age at onset, 40.4 [28.8-56.1] years; 125 female [52.1%]) with median (IQR) disease duration of 3.07 (1.95-6.15) years were included. A total of 110 of 240 patients (45.8%) relapsed after a median (IQR) of 0.45 (0.18-1.68) years, and 29 of 116 patients (25.0%) experienced a conversion to seronegative MOG-IgG. Both the time to treatment of the first MOGAD attack (late vs early: adjusted hazard ratio [aHR], 2.64; 95% CI, 1.43-4.84; P = .002; intermediate vs early: aHR, 2.02; 95% CI, 1.10-3.74; P = .02) and NSIS maintenance treatment (aHR, 0.24; 95% CI, 0.14-0.42; P &amp;lt; .001) were independently associated with the risk of relapse. In a subgroup without NSIS maintenance, the time to treat of the first MOGAD attack was still associated with higher risk of relapse (late vs early: aHR, 3.51; 95% CI, 1.64-7.50; P = .001; intermediate vs early: aHR, 2.68; 95% CI, 1.23-5.85; P = .01). Lastly, the time to treat of the first MOGAD attack was also associated with MOG-IgG seronegative conversion (early vs late: adjusted odds ratio, 7.04; 95% CI, 1.58-31.41; P = .01), whereas NSIS maintenance treatment was not.

Conclusions and Relevance

Results of this cohort study suggest that early treatment of the first acute MOGAD attack was associated with a reduction in the proportion of relapsing disease course and an increase in the likelihood of MOG-IgG seronegative conversion. These data suggest that timing of acute phase treatment for the first MOGAD attack can be associated with the long-term prognosis and autoimmune status of patients.